The Good, the Bad, the Question–<i>H19</i> in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is challenging to treat due to its typical late diagnosis, mostly at an advanced stage. Therefore, there is a particular need for research in diagnostic and prognostic biomarkers and therapeutic targets for HCC. The use of long no...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/5/1261 |
| _version_ | 1797567807151407104 |
|---|---|
| author | Lysann Tietze Sonja M. Kessler |
| author_facet | Lysann Tietze Sonja M. Kessler |
| author_sort | Lysann Tietze |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC), the most common primary liver cancer, is challenging to treat due to its typical late diagnosis, mostly at an advanced stage. Therefore, there is a particular need for research in diagnostic and prognostic biomarkers and therapeutic targets for HCC. The use of long noncoding (lnc) RNAs can widen the list of novel molecular targets improving cancer therapy. In hepatocarcinogenesis, the role of the lncRNA <i>H19</i>, which has been known for more than 30 years now, is still controversially discussed. <i>H19</i> was described to work either as a tumor suppressor in vitro and in vivo, or to have oncogenic features. This review attempts to survey the conflicting study results and tries to elucidate the potential reasons for the contrary findings, i.e., different methods, models, or readout parameters. This review encompasses in vitro and in vivo models as well as studies on human patient samples. Although the function of <i>H19</i> in HCC remains elusive, a short outlook summarizes some ideas of using the <i>H19</i> locus as a novel target for liver cancer therapy. |
| first_indexed | 2024-03-10T19:47:42Z |
| format | Article |
| id | doaj.art-7dcdd48cc5064123b151883372972aae |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:47:42Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7dcdd48cc5064123b151883372972aae2023-11-20T00:42:21ZengMDPI AGCancers2072-66942020-05-01125126110.3390/cancers12051261The Good, the Bad, the Question–<i>H19</i> in Hepatocellular CarcinomaLysann Tietze0Sonja M. Kessler1Institute of Pharmacy, Experimental Pharmacology for Natural Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), GermanyInstitute of Pharmacy, Experimental Pharmacology for Natural Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), GermanyHepatocellular carcinoma (HCC), the most common primary liver cancer, is challenging to treat due to its typical late diagnosis, mostly at an advanced stage. Therefore, there is a particular need for research in diagnostic and prognostic biomarkers and therapeutic targets for HCC. The use of long noncoding (lnc) RNAs can widen the list of novel molecular targets improving cancer therapy. In hepatocarcinogenesis, the role of the lncRNA <i>H19</i>, which has been known for more than 30 years now, is still controversially discussed. <i>H19</i> was described to work either as a tumor suppressor in vitro and in vivo, or to have oncogenic features. This review attempts to survey the conflicting study results and tries to elucidate the potential reasons for the contrary findings, i.e., different methods, models, or readout parameters. This review encompasses in vitro and in vivo models as well as studies on human patient samples. Although the function of <i>H19</i> in HCC remains elusive, a short outlook summarizes some ideas of using the <i>H19</i> locus as a novel target for liver cancer therapy.https://www.mdpi.com/2072-6694/12/5/1261H19IGF2miR-675HCCDMRimprinted gene |
| spellingShingle | Lysann Tietze Sonja M. Kessler The Good, the Bad, the Question–<i>H19</i> in Hepatocellular Carcinoma Cancers H19 IGF2 miR-675 HCC DMR imprinted gene |
| title | The Good, the Bad, the Question–<i>H19</i> in Hepatocellular Carcinoma |
| title_full | The Good, the Bad, the Question–<i>H19</i> in Hepatocellular Carcinoma |
| title_fullStr | The Good, the Bad, the Question–<i>H19</i> in Hepatocellular Carcinoma |
| title_full_unstemmed | The Good, the Bad, the Question–<i>H19</i> in Hepatocellular Carcinoma |
| title_short | The Good, the Bad, the Question–<i>H19</i> in Hepatocellular Carcinoma |
| title_sort | good the bad the question i h19 i in hepatocellular carcinoma |
| topic | H19 IGF2 miR-675 HCC DMR imprinted gene |
| url | https://www.mdpi.com/2072-6694/12/5/1261 |
| work_keys_str_mv | AT lysanntietze thegoodthebadthequestionih19iinhepatocellularcarcinoma AT sonjamkessler thegoodthebadthequestionih19iinhepatocellularcarcinoma AT lysanntietze goodthebadthequestionih19iinhepatocellularcarcinoma AT sonjamkessler goodthebadthequestionih19iinhepatocellularcarcinoma |